Assembly Biosciences (NASDAQ:ASMB) Upgraded at Zacks Research

Assembly Biosciences (NASDAQ:ASMB) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other research firms have also recently commented on ASMB. Guggenheim reiterated a “buy” rating and set a $43.00 target price on shares of Assembly Biosciences in a research note on Thursday, May 28th. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the company an “outperform” rating in a research report on Monday, June 15th. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Assembly Biosciences Trading Up 2.5%

Shares of ASMB opened at $34.38 on Thursday. The stock has a 50 day moving average of $27.11 and a 200 day moving average of $27.60. The company has a market capitalization of $700.01 million, a price-to-earnings ratio of 33.71 and a beta of 1.10. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.52. The business had revenue of $13.37 million for the quarter, compared to analysts’ expectations of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. As a group, equities research analysts predict that Assembly Biosciences will post 2.28 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. bought a new position in shares of Assembly Biosciences during the 3rd quarter worth $26,122,000. Paradigm Biocapital Advisors LP bought a new stake in Assembly Biosciences in the 4th quarter valued at about $22,625,000. Parkman Healthcare Partners LLC bought a new stake in Assembly Biosciences in the 3rd quarter valued at about $6,425,000. Vanguard Group Inc. lifted its holdings in Assembly Biosciences by 97.8% during the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after purchasing an additional 248,287 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Assembly Biosciences during the fourth quarter valued at about $5,476,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

More Assembly Biosciences News

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $2.28 from $1.90 and maintained a “Buy” rating with a $50 price target, signaling improved expectations for the company’s near-term earnings. HC Wainwright Assembly Biosciences estimates
• Positive Sentiment: The analyst also raised estimates for several periods, including Q3 2026 EPS to a loss of $0.44 from a loss of $0.69, Q1 2027 EPS to positive $0.02 from a loss of $0.16, and FY2027 EPS to a loss of $0.02 from a loss of $0.77. These revisions suggest expectations for a substantially better earnings trajectory.
• Positive Sentiment: Assembly Biosciences was added to Zacks’ Rank #1 (Strong Buy) list and its momentum-focused Strong Buy list. Such rankings may attract momentum-oriented investors, although they are based largely on quantitative factors. Zacks momentum stocks
• Positive Sentiment: Analysts continue to show constructive sentiment: HC Wainwright reiterated its “Buy” rating, while the broader analyst consensus was reported as “Moderate Buy.” Another Zacks analysis cited average analyst price targets implying significant potential upside, while cautioning that price targets are an imperfect forecasting tool. HC Wainwright Buy rating
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $3.19 from $3.69, partially offsetting the broader upward revisions. The company remains dependent on future earnings improvements, and analyst forecasts for some 2027 quarters still call for losses.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.